Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 259.46% | 170.51% | 305.16% | 235.50% | 258.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.53% | 161.94% | 99.57% | 132.90% | 258.48% |
| Operating Income | -68.53% | -161.94% | -99.57% | -132.90% | -258.48% |
| Income Before Tax | -57.27% | -139.07% | -76.68% | -105.60% | -276.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.27% | -139.07% | -76.68% | -105.60% | -276.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.27% | -139.07% | -76.68% | -105.60% | -276.97% |
| EBIT | -68.53% | -161.94% | -99.57% | -132.90% | -258.48% |
| EBITDA | -69.19% | -163.23% | -99.08% | -130.68% | -255.33% |
| EPS Basic | 87.33% | 80.74% | 85.74% | 67.20% | -275.04% |
| Normalized Basic EPS | 87.33% | 80.75% | 84.47% | 64.63% | -275.03% |
| EPS Diluted | 87.33% | 80.74% | 85.74% | 67.20% | -275.04% |
| Normalized Diluted EPS | 87.33% | 80.75% | 84.47% | 64.63% | -275.03% |
| Average Basic Shares Outstanding | 1,141.70% | 1,141.58% | 1,138.73% | 526.83% | 0.52% |
| Average Diluted Shares Outstanding | 1,141.70% | 1,141.58% | 1,138.73% | 526.83% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |